HREVS: Hybrid Revascularization Offers No Advantage in Multivessel Disease

Courtesy of SBHCI.

Hybrid revascularization, which combines CABG with PCI, failed to reduce myocardial ischemia and major cardiac and cerebrovascular events, compared to cardiac artery bypass graft  or PCI separately.

HREVS: la revascularización híbrida no ofrece ventajas en la enfermedad de múltiples vasos

However, this small study does not provide conclusive evidence, which calls for further randomized studies with enough statistical power to answer this question. Fortunately, we won’t have to wait long, since at   present there the HYBRID study is in progress, with a 5 year follow up and more than 2300 patients with multivessel disease randomized to hybrid revascularization vs. PCI.


Read also: CULPRIT-SHOCK Results Will Transform Guidelines and Clinical Practice”.


The small HREVS study included 155 patients (50 undergoing surgery alone, 53 PCI alone and 52 hybrid revascularization). Hybrid revascularization included minimally invasive surgery with mammary bypass to the anterior descending artery, followed by PCI between 1 and 3 days after, with DES to all remaining vessels.

 

The study did not have power to show clinical end points, but there were significant differences at 30 days.

 

Gentileza de la SBHCI.

 

Original title: HREVS: a randomized trial of PCI vs CABG vs hybrid revascularization in patients with coronary artery disease.

Presenter: Tarasov R.

 

HREVS-study


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...